Bumpy Ride Awaits Indian Firms In 2018 (And Then There’s Amazon)
Executive Summary
2018 may not be smooth sailing for Indian firms, going by the predictions of top industry pundits. Possible upheavals on the domestic market, dynamics that demand a hawk eye on expenses and gains but also pressures as a result of FDA reforms suggest that a relatively tough year may be in store.
You may also be interested in...
Amazon Hurricane Heading Towards Indian Pharma?
Think Amazon, think disruption, and that’s exactly what could be in store if the online retail juggernaut goes through with its rumored plans to invest in MedPlus, India’s second largest retail pharmacy chain. A deal could also have ramifications for private equity/venture capital activity in the Indian pharmacy space, say some experts.
What ‘Modicare’ May Mean (Or Not) For Pharma In India
Ambitious and complex to say the least, India’s “Modicare” – the proposed National Health Protection Scheme – could have significant implications on market expansion in the country. Scrip brings you an early take from pharma industry experts on what to expect (or not) and where the key challenges lie.
CVS/Aetna To Merge In Defensive Play To Reshape Health-Care Delivery
The pharmacy retail chain and drug distributor will buy the insurer for $69bn in a merger to build what the companies say will be a new, more affordable health-care concept.